Gennova Biopharmaceuticals gets DCGI nod for mRNA-based Covid booster vaccine
GEMCOVAC-OM is the first booster Covid-19 vaccine developed in India against the highly transmissible Omicron variant.
GEMCOVAC-OM is the first booster Covid-19 vaccine developed in India against the highly transmissible Omicron variant.
The results show no adverse effects were seen in clinical trials; the company says the vaccine is an alternative for those hesitant to receive mRNA jabs in the U.S.
Gennova's vaccine will be available for adults above 18 years of age. It will be a two-dose vaccine that will be administered intramuscularly at 28 days apart
Peer-reviewed data has been published in Lancet Infectious Diseases; phase II-III study was held to evaluate safety, and immunogenicity of COVAXIN among healthy children and adolescents.
The CDSCO approval has also been granted for two doses of ZyCov-D for those aged over 12. The decision comes amid a rise in Covid cases in cities like Delhi.
In addition to the US and Canada, Ocugen will also have the exclusive rights for supply and commercialisation of Covaxin in Mexico.
Booster shots for healthcare and frontline workers to start from Jan 10; those above 60, with comorbities, eligible too.
Ella was the company’s go-to person during the production of its indigenously developed Covid-19 vaccine, Covaxin—engaging with multiple ministries almost on a daily basis.
100 crore shots and rising.
As countries open their borders to travel, tourism and education, Bharat Biotech’s Covaxin awaits WHO’s nod on October 26. Co-founder, Suchitra Ella, is hopeful of a positive answer.